Bayer Lands €3 Billion Apollo Deal to Fortify Balance Sheet Amid Regulatory and Legal Crosswinds

Bayer raises €3B from Apollo for its LARC unit to refinance debt and cover Roundup costs; stock up 79% y/y but volatility high as healthcare law and settlement hearing loom.

Bayer has pulled off a financial maneuver that buys it breathing room on two of its most pressing fronts. The German life-sciences group is funneling roughly €3 billion in fresh equity from US private-equity firm Apollo Global Management into a newly created subsidiary that houses its long-acting reversible contraceptives (LARC) business. Chief Financial Officer Judith Hartmann framed the move as a way to generate financial flexibility, giving Bayer the liquidity to refinance maturing bonds and cover the multibillion-dollar legal legacy from Roundup lawsuits in the United States. Crucially, the company retains full operational control of the LARC unit, which generated nearly €1.4 billion in revenue last year. The deal is expected to close in the third quarter of 2026.

The infusions comes at a moment when Bayer’s stock has been on a tear. Investors who bought in a year ago are sitting on a gain of 79.26%, and the shares have climbed 30.70% since the start of 2026. Yet the rally took a pause on Friday, with the stock slipping 1.97% to €49.70 — a classic consolidation after a sprint. The 52-week high of €53.86, reached on July 3, now lies 7.72% above the current price. The Relative Strength Index (RSI) stands at 68.1, inching toward overbought territory, while annualized 30-day volatility remains elevated at 62.25%.

That high volatility reflects the twin external pressures Bayer continues to navigate. On the home front, Germany’s Bundestag on Friday passed the GKV-Beitragssatzstabilisierungsgesetz — a sweeping healthcare cost-containment law that targets €18.8 billion in savings from 2027. Higher patient co-payments and cuts to dental prosthetics are part of the package, but the pharmaceutical industry fears the real blow will come from tighter price caps and rebate rules. The sector has already warned of potential investment cuts, a risk that weighs on long-term margin expectations for Bayer’s pharma division.

Across the Atlantic, the legal picture has brightened but remains unresolved. A recent U.S. Supreme Court ruling — which affirmed that federal pesticide-labeling law preempts state-level warning requirements — has undercut many of the remaining Roundup lawsuits. Bayer has used that momentum to seek dismissal of roughly 4,000 claims. Yet the broader settlement, valued at $7.25 billion, still awaits a fairness hearing that has been pushed back from July 9 to August 19. The judge is expected to decide whether to approve the deal covering a large chunk of the outstanding state-court cases. Until then, the stock remains tethered to courtroom developments.

Two more dates are now circled on investors’ calendars. On August 4, Bayer will publish its second-quarter 2026 earnings, offering a fresh look at operational performance. And on August 19, the settlement hearing will determine whether the company can put a significant portion of its legal exposure behind it. With the stock already at elevated levels and volatility high, any misstep from Berlin or a further delay in the courtroom could trigger a swift pullback. For now, the Apollo deal gives Bayer the financial cushion to weather those crosswinds — but it hasn’t eliminated them.